Home Cart Sign in  
Chemical Structure| 171746-21-7 Chemical Structure| 171746-21-7

Structure of AGN 193109
CAS No.: 171746-21-7

Chemical Structure| 171746-21-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AGN 193109 is a high affinity pan-retinoic acid receptor (RAR) antagonist with Kds of 2, 2 and 3 nM at RARα, RARβ and RARγ, respectively.

Synonyms: AGN 193109

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AGN 193109

CAS No. :171746-21-7
Formula : C28H24O2
M.W : 392.49
SMILES Code : CC(CC=C1C2=CC=C(C)C=C2)(C)C(C1=C3)=CC=C3C#CC4=CC=C(C(O)=O)C=C4
Synonyms :
AGN 193109
MDL No. :MFCD00943817
InChI Key :NCEQLLNVRRTCKJ-UHFFFAOYSA-N
Pubchem ID :177238

Safety of AGN 193109

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
human limbal epithelial cells (LEC) 0.5 µM, 1.0 µM, 1.5 µM 24 h and 48 h AGN 193109 treatment led to the upregulation of ADH7, KRT3, and DSG1 mRNA expression and to the downregulation of KRT12 and KRT19 mRNA expression. 2021 Nov 8;11(11):1651. doi: 10.3390/biom11111651.
Human coronary artery smooth muscle cells (SMC) 0.1 μmol/L or 1 μmol/L two weeks or three weeks AGN 193109 dose-dependently increased SMC mineralization, indicating a selective RARα-mediated mechanism for ATRA-induced inhibition of human SMC calcification. Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):656-669
primary porcine RPE cells 1 µM AGN 193109 did not significantly affect A2E-induced RXR transactivation Int J Mol Sci. 2024 Mar 6;25(5):3037

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice MCMV infection model Oral 25 mg/kg 2 hours pre-infection and on days 2, 4, 7, 9, 11, and 14 post-infection To evaluate the effects of ATRA and AGN 193109 on MCMV infection, results showed ATRA exacerbated infection (reduced LD50), while AGN 193109 antagonized ATRA's adverse effects. J Virol. 1998 Jun;72(6):4589-600

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.25mL

12.74mL

2.55mL

1.27mL

25.48mL

5.10mL

2.55mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories